Form 4: Atara Biotherapeutics CEO Acquires 45,000 Shares of Common Stock
SEC Form 4 Filing
Atara Biotherapeutics' CEO, AnhCo Nguyen, acquired 45,000 shares of common stock on September 9, 2024, and disposed of 79,118 shares.
Summary
- On September 9, 2024, AnhCo Nguyen, the President and CEO of Atara Biotherapeutics, acquired 45,000 shares of Atara Biotherapeutics common stock.
- The acquisition was in the form of restricted stock units (RSUs).
- Nguyen also disposed of 79,118 shares of common stock.
- Following the transaction, Nguyen directly owns 79,118 shares of Atara Biotherapeutics common stock.
- The RSUs vest in installments over time, contingent upon continuous service.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Future Outlook
The restricted stock units vest quarterly, subject to the reporting person's continuous service.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings provide transparency to the market about insider activity.
Stakeholder Impact
- Shareholders may be interested in the CEO's stock transactions as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 09/09/2024 | Date of transaction: CEO acquired 45,000 shares of common stock and disposed of 79,118 shares. |
| 09/11/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.